Showing results (51-60 of 103) with videos related to

Sort By:
Pageof 11
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2000
A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative GroupJ B Vermorken, A Kobierska, B Chevallier, et al.
The International Journal of Biological Markers|July 1, 1990
Clinical value of radioimmunoscintigraphy in the follow-up of ovarian carcinoma: a prospective studyF Crippa, M Presti, A Marini, et al.
Tumori|April 30, 1988
Drug sensitivity of different tumor lesions from the same patient evaluated by a short-term assayN Zaffaroni, R Silvestrini, O Sanfilippo, et al.
British Journal of Cancer|March 26, 1998
Determinants of risk of invasive cervical cancer in young womenF Parazzini, L Chatenoud, C La Vecchia, et al.
The Journal of Reproductive Medicine|July 1, 1992
Laparoscopic aspiration of ovarian endometriomas. Effect with postoperative gonadotropin releasing hormone agonist treatmentP Vercellini, N Vendola, L Bocciolone, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trialC Sessa, G Bolis, N Colombo, et al.
European Journal of Cancer (Oxford, England : 1990)|December 9, 1997
Ovarian cancer risk and history of selected medical conditions linked with female hormonesF Parazzini, S Moroni, C La Vecchia, et al.
Gynecologic Oncology|November 1, 1988
EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT)G Bolis, C Bonazzi, F Landoni, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1980
Low-dose cyclophosphamide versus adriamycin plus cyclophosphamide in advanced ovarian cancer. A randomized clinical studyG Bolis, G Bortolozzi, G Carinelli, et al.
Gynecologic Oncology|July 1, 1999
Pelvic and paraortic lymph nodal status in advanced ovarian cancer and survivalF Parazzini, G Valsecchi, G Bolis, et al.
Pageof 11